New research has found that an investigational targeted therapy called CD45-ADC can reset the normal function of the immune system in a mouse model of multiple sclerosis (MS). CD45-ADC is an antibody-drug conjugate that’s being developed to treat different types of autoimmune diseases. Researchers found that a single dose was enough to be effective to reset normal function and delay the onset of MS. The drug works by destroying overactive immune cells that have the CD45 protein on their surface. It delivers amanitin – a toxin produced by certain species of mushroom – to them, leaving normal immune cells and therefore restoring normal function.
The scientists also discovered that following the treatment up with a stem cell transplant to repopulate the mice’s bodies with healthy immune cells delayed the disease onset and halted its progression.
CD45-ADC is also showing promising results for treating mouse models of two other autoimmune diseases, systemic sclerosis (scleroderma) and inflammatory arthritis.
Source: MS-UK 21/11/2019